Rallybio Files 8-K on Operations, Exit Costs

TL;DR

**Rallybio just filed an 8-K hinting at financial results and potential restructuring.**

AI Summary

Rallybio Corp. filed an 8-K on February 6, 2024, indicating a current report regarding 'Results of Operations and Financial Condition' and 'Cost Associated with Exit or Disposal Activities.' This suggests the company is likely announcing financial results and potentially restructuring or discontinuing certain operations, which could impact future profitability and the stock's valuation. Investors should pay close attention to the details of these announcements as they will reveal the company's financial health and strategic direction.

Why It Matters

This filing signals upcoming financial disclosures and potential operational changes, which are crucial for investors to assess Rallybio's current performance and future prospects.

Risk Assessment

Risk Level: medium — The mention of 'Cost Associated with Exit or Disposal Activities' introduces uncertainty about the scope and financial impact of potential operational changes.

Analyst Insight

A smart investor would await the full details of the financial results and the nature of the 'exit or disposal activities' before making any significant investment decisions, as these could significantly impact the company's valuation.

Key Numbers

• 20240206 — Filing Date (The date the 8-K was filed, indicating recent activity.)
• 001-40693 — SEC File Number (Unique identifier for Rallybio's filings with the SEC.)

Key Players & Entities

• Rallybio Corp (company) — the registrant filing the 8-K
• 001-40693 (dollar_amount) — Commission File Number
• 85-1083789 (dollar_amount) — IRS Employer Identification No.
• February 6, 2024 (date) — Date of earliest event reported
• RLYB (company) — Trading Symbol for Common Stock

Forward-Looking Statements

• Rallybio Corp. will release detailed financial results for a recent period soon. (Rallybio Corp.) — high confidence, target: Q1 2024
• The company will provide specifics on the 'Exit or Disposal Activities' mentioned. (Rallybio Corp.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share RLYB NASDAQ Global Select Mar
• $3.3 m — pects to incur charges of approximately $3.3 million, excluding share-based compensati

Filing Documents

• rlyb-20240206.htm (8-K) — 30KB
• rlyb-202462xex991.htm (EX-99.1) — 23KB
• 0001739410-24-000012.txt ( ) — 191KB
• rlyb-20240206.xsd (EX-101.SCH) — 2KB
• rlyb-20240206_lab.xml (EX-101.LAB) — 25KB
• rlyb-20240206_pre.xml (EX-101.PRE) — 13KB
• rlyb-20240206_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 6, 2024, Rallybio Corporation (Rallybio) issued a press release (the Press Release) that contained an estimate of its cash, cash equivalents and marketable securities as of December 31, 2023. This information is preliminary and unaudited. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On February 6, 2024, Rallybio announced the prioritization of its portfolio and a workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116. As part of this effort, Rallybio will eliminate approximately 45% of its current positions. As a result of these actions, Rallybio expects to incur charges of approximately $3.3 million, excluding share-based compensation expense. The charges related to the workforce reduction are cash-based expenditures related primarily to one-time severance and benefit payments. Rallybio expects to recognize substantially all charges related to the workforce reduction in the quarter ending March 31, 2024. These estimates are subject to assumptions and actual results may differ. In connection with the announcement, Rallybio issued the Press Release, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Forward-Looking Statements

Forward-Looking Statements This Current Report contains forward looking statements that are based on our management's beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this Current Report are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, estimated expenses to be incurred in connection with Rallybio's planned workforce reduction and other statements related to the planned workforce reduction. The forward-looking statements in this Current Report are only predictions and are based largely on management's current expectations and projections about future events and financial trends that management believes may affect Rallybio's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Current Report and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to risks and uncertainties described in Rallybio's filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio's Quarterly Report on Form 10-Q for the period ended September 30, 2023, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Rallybio is not obligated to publicly update or revise any

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on February 6, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. RALLYBIO CORPORATION Date: February 6, 2024 By: /s/ Jonathan I. Lieber Jonathan I. Lieber Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR